Bruker Corporation Announces Quarterly Dividend of $0.05 (NASDAQ:BRKR)

Bruker Corporation (NASDAQ:BRKR) declared a quarterly dividend on Friday, August 14th. Investors of record on Monday, September 21st will be given a dividend of 0.05 per share by the medical research company on Wednesday, October 7th. This represents a c) annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 21st.

Bruker has increased its dividend payment by an average of 0.0%annually over the last three years. Bruker has a payout ratio of 7.3% meaning its dividend is sufficiently covered by earnings. Analysts expect Bruker to earn $2.43 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 8.2%.

Bruker Trading Down 2.6%

Shares of BRKR opened at $61.39 on Friday. Bruker has a 1-year low of $30.09 and a 1-year high of $65.30. The company has a 50-day moving average of $58.17 and a 200 day moving average of $49.90. The firm has a market capitalization of $9.35 billion, a price-to-earnings ratio of -87.70, a PEG ratio of 1.93 and a beta of 1.26. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts expect that Bruker will post 2.12 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays boosted their price target on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Wolfe Research initiated coverage on Bruker in a research report on Monday, June 1st. They set a “peer perform” rating for the company. Zacks Research cut Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Guggenheim increased their price target on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Citigroup cut their price target on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Bruker currently has an average rating of “Hold” and an average target price of $57.00.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.